ASX:BDX BCAL Diagnostics (BDX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About BCAL Diagnostics Stock (ASX:BDX) 30 days 90 days 365 days Advanced Chart Get BCAL Diagnostics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationA$36.60 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a non-invasive blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from patient's blood plasma to diagnose the presence of breast cancer cells in a patient's body. The company was incorporated in 2010 and is headquartered in Sydney, Australia. Read More Receive BDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BCAL Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BDX Stock News HeadlinesBCAL Diagnostics Releases 2025 Corporate Governance StatementAugust 29, 2025 | tipranks.comBCAL Diagnostics Launches Innovative Breast Cancer TestAugust 28, 2025 | tipranks.comForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it could transform warfare, robotics, and the global economy. But you don’t need to buy Tesla or wait for xAI to IPO to benefit. One overlooked public company is supplying the critical tech behind Musk’s AI push — and it trades for a fraction of Nvidia’s price. Hedge funds are already loading up, but most investors haven’t noticed yet. | Behind the Markets (Ad)Becton, Dickinson and Company: A Solid Divestment For Its Bioscience And Diagnostics BusinessJuly 15, 2025 | seekingalpha.comBCAL Diagnostics Stock Price History - Investing.comJuly 5, 2025 | investing.comASX:BDX Financials | BCAL Diagnostics Ltd - Investing.comJuly 2, 2025 | investing.comBCAL Diagnostics Expands BREASTEST plus Access in Sydney and MelbourneMay 5, 2025 | tipranks.comBecton, Dickinson, and Company (BDX): Among the Best Falling Stocks to Buy According to AnalystsMay 4, 2025 | msn.comSee More Headlines BDX Stock Analysis - Frequently Asked Questions What other stocks do shareholders of BCAL Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that BCAL Diagnostics investors own include Chevron (CVX), JPMorgan Chase & Co. (JPM), Bristol Myers Squibb (BMY), 3M (MMM), NextEra Energy (NEE), ONEOK (OKE) and Tesla (TSLA). Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Diagnostics & Research Sub-IndustryMedical Equipment Current SymbolASX:BDX CIKN/A Webwww.bd.com Phone12018476800FaxN/AEmployees77,000Year FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$6.40 million Net Margins-295.31% Pretax MarginN/A Return on Equity-87.34% Return on Assets-36.51% Debt Debt-to-Equity Ratio17.74 Current Ratio3.60 Quick Ratio6.70 Sales & Book Value Annual SalesA$3.10 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueA$0.03 per share Price / BookN/AMiscellaneous Outstanding Shares358,660,000Free FloatN/AMarket CapA$36.60 million OptionableNot Optionable Beta0.69 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (ASX:BDX) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredFree: The Crypto Summit That Could Change Your LifeWall Street’s Crypto Playbook—Revealed at This Free Event If you want to understand what's really happening...Crypto 101 Media | SponsoredReagan’s former tech advisor sharing bombshell announcementGeorge Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BCAL Diagnostics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share BCAL Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
